Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Concert Pharmaceuticals, a clinical stage biotechnology company, has initiated a Phase I study in healthy volunteers to evaluate the safety, tolerability and pharmacokinetics of CTP-347, a novel deuterium-containing serotonin modulator created by Concert researchers.
Subscribe to our email newsletter
Concert intends to evaluate CTP-347 as a non-hormonal treatment for vasomotor symptoms or hot flashes in patients with increased risk of adverse effects due to, or contraindicated to using, hormone therapy, as well as in the larger menopausal population. Results of this Phase I study are expected to be available in the first half of 2009.
The company expects to investigate CTP-347’s drug-drug interaction profile as part of the Phase I study.
Roger Tung, president and CEO of Concert Pharmaceuticals, said: “We are pleased to have advanced our first compound from concept to clinical testing in less than two years.
“We believe our deuterium chemistry platform holds great promise in creating novel compounds with superior safety and efficacy as compared to existing therapies. We look forward to advancing and introducing a number of first-in-class agents for unmet medical needs, of which CTP-347 is our first to enter the clinic.”